“By centralizing data from disparate sources and modernizing how trial and operational data are viewed, the ERT Business Intelligence suite enables trial sponsors and CROs to gain more powerful insights from clinical trial data and keep their trials on track and on budget.”
PHILADELPHIA (PRWEB) June 04, 2018
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today introduced its all-new Business Intelligence suite to deliver enhanced clinical trial reporting and analytics, enabling sponsors and contract research organizations (CROs) to make more proactive, better-informed decisions and improve clinical trial efficiencies.
Offering a range of online reporting solutions, as well as real-time analytics using all trial data, ERT Business Intelligence delivers comprehensive, actionable insights across one or multiple studies. Data are housed and mastered in ERT’s proprietary operational data store, which is built on the Amazon Web Services platform, a cloud-based, scalable data infrastructure that serves as the foundation for all of ERT’s ongoing and future product development initiatives.
Clinical trial complexities have increased exponentially in recent years, creating significant data aggregation, management and reporting challenges. In addition to as many as 12 different data capture systems being used in any given study, the average number of sites and endpoints per trial have increased by 58% and 70%+ respectively, in recent years.
ERT’s Business Intelligence suite enables centralized clinical trial data capture from multiple disparate sources – whether via ERT’s safety and efficacy endpoint solutions or other clinical and operational data feeds. The application creates uniformity and shares integrated data through an intuitive user interface for easy consumption via Standardized, Configurable or Custom reports.
“Our customers have stressed the importance of improving operational efficiency, speed, quality and insights in order to reduce clinical development costs and timelines,” says Prakriteswar Santikary, PhD, Chief Data Officer, ERT. “By centralizing data from disparate sources and modernizing how trial and operational data are viewed, the ERT Business Intelligence suite enables trial sponsors and CROs to gain more powerful insights from clinical trial data and keep their trials on track and on budget.”
Visit ert.com/trial-oversight for more information on ERT’s Business Intelligence suite.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2017, ERT supported more than 60% of all FDA drug approvals. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.